Update information
Minor changes since publication
March 2025: In section 1.6 we removed the link to NICE technology appraisal guidance on andexanet alfa (TA697) because the guidance has been updated and no longer applies to this guideline.
August 2023: We added links to the MHRA safety advice on DOACs and NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697) to the section on prothrombin complex concentrate.
March 2022: A link to MHRA advice on intravenous iron was removed from recommendation 1.1.3.
July 2020: A link to MHRA advice on intravenous iron was added to recommendation 1.1.3. A link to the NICE guideline on joint replacement (primary) was added to recommendation 1.1.5 to give advice on tranexamic acid in primary hip, knee and shoulder replacement.
ISBN: 978‑1‑4731‑1527‑9